发现口服可用的和穿透大脑的AEP抑制剂
Daniela Krummenacher1, Weiping He2, Bernd Kuhn1
1Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel CH-4070, Switzerland.
研究人员开发了针对阿斯巴拉金内酶 (AEP) 的新药,以抑制有毒tau碎片的形成,这是阿尔茨海默病 (AD) 的标志. 这些口服可用的抑制剂显示出降低阿尔茨海默氏症病理学的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因.
- 由化Tau组成的神经纤维状 (NFT) 是AD的关键病理特征.
- 阿斯巴拉金内酶 (AEP) 切割Tau,产生与AD病理学相关的聚合易感碎片.
研究的目的:
- 开发针对AEP的新型抑制剂,作为潜在的阿尔茨海默病治疗策略.
- 确定具有不可逆转结合模式的选择性,口服生物可用和脑透的AEP抑制剂.
- 为了确定AEP抑制和毒性Tau碎片的减少之间的治疗联系.
主要方法:
- 药物发现和开发管道,从可逆抑制剂开始.
- 具有不可逆转结合的选择性抑制剂的特征.
- 在体外和体内研究以评估AEP抑制和Tau N368片段水平.
主要成果:
- 第一份关于正经,选择性,口服生物可用性和脑透性AEP抑制剂的报告.
- 对于开发的抑制剂,已经证明了不可逆转的结合模式.
- 在AEP抑制后,在体外和体内都证实了TAU N368碎片水平的降低.
结论:
- 用新型不可逆转的抑制剂向AEP代表了阿尔茨海默病的有希望的治疗策略.
- 开发的抑制剂是口服生物可用和脑透,促进潜在的临床应用.
- 抑制AEP有效地减少了容易聚合的Tau碎片的形成,解决了AD的关键病理机制.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Drug Discovery: Overview
